AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VVOS
  4. [Form 3] Vivos Therapeutics, Inc. Initial Statement of Beneficial Ownership

[Form 3] Vivos Therapeutics, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Michael C. Skaff filed an initial Form 3 statement of beneficial ownership for Vivos Therapeutics (VVOS), reporting his position as a 10% owner. The filing details significant holdings through two investment vehicles:

Through V-CO Investors LLC:

  • 514,498 shares of common stock
  • Pre-Funded Warrant for 2,705,768 shares (exercise price: $0.0001, expires 2034)
  • Common Stock Purchase Warrant for 3,220,266 shares (exercise price: $2.204, expires 2029)

Through V-Co Investors 2 LLC:

  • 828,000 shares of common stock
  • Pre-Funded Warrant for 725,258 shares (exercise price: $0.0001, expires 2035)
  • Common Stock Purchase Warrant for 2,329,886 shares (exercise price: $2.23, expires 2030)

Skaff serves as Managing Director of SP Manager LLC, which manages both investment vehicles. He disclaims beneficial ownership except for his pecuniary interest.

Michael C. Skaff ha presentato una dichiarazione iniziale di propriet脿 beneficiaria tramite il modulo Form 3 per Vivos Therapeutics (VVOS), segnalando una posizione di proprietario del 10%. La dichiarazione evidenzia partecipazioni significative attraverso due veicoli di investimento:

Attraverso V-CO Investors LLC:

  • 514.498 azioni ordinarie
  • Warrant pre-finanziato per 2.705.768 azioni (prezzo di esercizio: $0,0001, scadenza 2034)
  • Warrant per l'acquisto di azioni ordinarie per 3.220.266 azioni (prezzo di esercizio: $2,204, scadenza 2029)

Attraverso V-Co Investors 2 LLC:

  • 828.000 azioni ordinarie
  • Warrant pre-finanziato per 725.258 azioni (prezzo di esercizio: $0,0001, scadenza 2035)
  • Warrant per l'acquisto di azioni ordinarie per 2.329.886 azioni (prezzo di esercizio: $2,23, scadenza 2030)

Skaff ricopre il ruolo di Managing Director presso SP Manager LLC, che gestisce entrambi i veicoli di investimento. Egli esclude la propriet脿 beneficiaria fatta eccezione per il suo interesse pecuniario.

Michael C. Skaff present贸 una declaraci贸n inicial en el Formulario 3 sobre la propiedad beneficiaria de Vivos Therapeutics (VVOS), reportando una posici贸n como propietario del 10%. La presentaci贸n detalla participaciones significativas a trav茅s de dos veh铆culos de inversi贸n:

A trav茅s de V-CO Investors LLC:

  • 514,498 acciones ordinarias
  • Warrant prefinanciado para 2,705,768 acciones (precio de ejercicio: $0.0001, vence en 2034)
  • Warrant para compra de acciones ordinarias para 3,220,266 acciones (precio de ejercicio: $2.204, vence en 2029)

A trav茅s de V-Co Investors 2 LLC:

  • 828,000 acciones ordinarias
  • Warrant prefinanciado para 725,258 acciones (precio de ejercicio: $0.0001, vence en 2035)
  • Warrant para compra de acciones ordinarias para 2,329,886 acciones (precio de ejercicio: $2.23, vence en 2030)

Skaff es Director General de SP Manager LLC, que administra ambos veh铆culos de inversi贸n. 脡l renuncia a la propiedad beneficiaria excepto por su inter茅s pecuniario.

毵堨澊韥� C. 鞀れ勾頂�電� Vivos Therapeutics(VVOS)鞐� 雽�頃� 齑堦赴 Form 3 鞙犾澋 靻岇湢甓� 鞁犼碃靹滊ゼ 鞝滌稖頄堨溂氅�, 10% 靻岇湢鞛愲靹滌潣 歆�鞙勲ゼ 氤搓碃頄堨姷雼堧嫟. 鞚� 鞁犼碃靹滊姅 霊� 臧滌潣 韴瀽 靾橂嫧鞚� 韱淀暅 靸侂嫻頃� 氤挫湢 雮挫棴鞚� 靸侅劯頌� 靹る獏頃╇媹雼�:

V-CO Investors LLC毳� 韱淀暣:

  • 514,498 氤错喌欤�
  • 靹犽秷 鞗岆煱韸� 2,705,768欤� (頄夓偓臧�瓴�: $0.0001, 毵岆: 2034雲�)
  • 氤错喌欤� 毵れ垬 鞗岆煱韸� 3,220,266欤� (頄夓偓臧�瓴�: $2.204, 毵岆: 2029雲�)

V-Co Investors 2 LLC毳� 韱淀暣:

  • 828,000 氤错喌欤�
  • 靹犽秷 鞗岆煱韸� 725,258欤� (頄夓偓臧�瓴�: $0.0001, 毵岆: 2035雲�)
  • 氤错喌欤� 毵れ垬 鞗岆煱韸� 2,329,886欤� (頄夓偓臧�瓴�: $2.23, 毵岆: 2030雲�)

鞀れ勾頂勲姅 霊� 韴瀽 靾橂嫧鞚� 甏�毽晿電� SP Manager LLC鞚� 鞝勲 鞚挫偓搿� 鞛 欷戩瀰雼堧嫟. 攴鸽姅 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃� 鞙犾澋 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.

Michael C. Skaff a d茅pos茅 une d茅claration initiale de propri茅t茅 b茅n茅ficiaire via le formulaire 3 pour Vivos Therapeutics (VVOS), indiquant une position de d茅tenteur de 10%. Le d茅p么t d茅taille des participations importantes via deux v茅hicules d'investissement :

Via V-CO Investors LLC :

  • 514 498 actions ordinaires
  • Warrant pr茅financ茅 pour 2 705 768 actions (prix d'exercice : 0,0001 $, expiration en 2034)
  • Warrant d'achat d'actions ordinaires pour 3 220 266 actions (prix d'exercice : 2,204 $, expiration en 2029)

Via V-Co Investors 2 LLC :

  • 828 000 actions ordinaires
  • Warrant pr茅financ茅 pour 725 258 actions (prix d'exercice : 0,0001 $, expiration en 2035)
  • Warrant d'achat d'actions ordinaires pour 2 329 886 actions (prix d'exercice : 2,23 $, expiration en 2030)

Skaff est directeur g茅n茅ral de SP Manager LLC, qui g猫re les deux v茅hicules d'investissement. Il d茅cline la propri茅t茅 b茅n茅ficiaire sauf pour son int茅r锚t p茅cuniaire.

Michael C. Skaff reichte eine erste Form 3-Erkl盲rung 眉ber den wirtschaftlichen Eigentum an Vivos Therapeutics (VVOS) ein und meldete eine Beteiligung von 10%. Die Einreichung beschreibt bedeutende Beteiligungen 眉ber zwei Investmentvehikel:

脺产别谤 V-CO Investors LLC:

  • 514.498 Stammaktien
  • Vorfinanzierte Optionsscheine f眉r 2.705.768 Aktien (Aus眉bungspreis: 0,0001 $, Ablauf 2034)
  • Optionsscheine zum Kauf von Stammaktien f眉r 3.220.266 Aktien (Aus眉bungspreis: 2,204 $, Ablauf 2029)

脺产别谤 V-Co Investors 2 LLC:

  • 828.000 Stammaktien
  • Vorfinanzierte Optionsscheine f眉r 725.258 Aktien (Aus眉bungspreis: 0,0001 $, Ablauf 2035)
  • Optionsscheine zum Kauf von Stammaktien f眉r 2.329.886 Aktien (Aus眉bungspreis: 2,23 $, Ablauf 2030)

Skaff ist Gesch盲ftsf眉hrer von SP Manager LLC, die beide Investmentvehikel verwaltet. Er lehnt das wirtschaftliche Eigentum ab, mit Ausnahme seines finanziellen Interesses.

Positive
  • Significant 10% ownership position established through substantial holdings: combined direct ownership of 1,342,498 common shares through investment vehicles
  • Large warrant position with potential ownership increase: rights to acquire additional 8,981,178 shares through various warrants, indicating strong commitment to the company
Negative
  • None.

Michael C. Skaff ha presentato una dichiarazione iniziale di propriet脿 beneficiaria tramite il modulo Form 3 per Vivos Therapeutics (VVOS), segnalando una posizione di proprietario del 10%. La dichiarazione evidenzia partecipazioni significative attraverso due veicoli di investimento:

Attraverso V-CO Investors LLC:

  • 514.498 azioni ordinarie
  • Warrant pre-finanziato per 2.705.768 azioni (prezzo di esercizio: $0,0001, scadenza 2034)
  • Warrant per l'acquisto di azioni ordinarie per 3.220.266 azioni (prezzo di esercizio: $2,204, scadenza 2029)

Attraverso V-Co Investors 2 LLC:

  • 828.000 azioni ordinarie
  • Warrant pre-finanziato per 725.258 azioni (prezzo di esercizio: $0,0001, scadenza 2035)
  • Warrant per l'acquisto di azioni ordinarie per 2.329.886 azioni (prezzo di esercizio: $2,23, scadenza 2030)

Skaff ricopre il ruolo di Managing Director presso SP Manager LLC, che gestisce entrambi i veicoli di investimento. Egli esclude la propriet脿 beneficiaria fatta eccezione per il suo interesse pecuniario.

Michael C. Skaff present贸 una declaraci贸n inicial en el Formulario 3 sobre la propiedad beneficiaria de Vivos Therapeutics (VVOS), reportando una posici贸n como propietario del 10%. La presentaci贸n detalla participaciones significativas a trav茅s de dos veh铆culos de inversi贸n:

A trav茅s de V-CO Investors LLC:

  • 514,498 acciones ordinarias
  • Warrant prefinanciado para 2,705,768 acciones (precio de ejercicio: $0.0001, vence en 2034)
  • Warrant para compra de acciones ordinarias para 3,220,266 acciones (precio de ejercicio: $2.204, vence en 2029)

A trav茅s de V-Co Investors 2 LLC:

  • 828,000 acciones ordinarias
  • Warrant prefinanciado para 725,258 acciones (precio de ejercicio: $0.0001, vence en 2035)
  • Warrant para compra de acciones ordinarias para 2,329,886 acciones (precio de ejercicio: $2.23, vence en 2030)

Skaff es Director General de SP Manager LLC, que administra ambos veh铆culos de inversi贸n. 脡l renuncia a la propiedad beneficiaria excepto por su inter茅s pecuniario.

毵堨澊韥� C. 鞀れ勾頂�電� Vivos Therapeutics(VVOS)鞐� 雽�頃� 齑堦赴 Form 3 鞙犾澋 靻岇湢甓� 鞁犼碃靹滊ゼ 鞝滌稖頄堨溂氅�, 10% 靻岇湢鞛愲靹滌潣 歆�鞙勲ゼ 氤搓碃頄堨姷雼堧嫟. 鞚� 鞁犼碃靹滊姅 霊� 臧滌潣 韴瀽 靾橂嫧鞚� 韱淀暅 靸侂嫻頃� 氤挫湢 雮挫棴鞚� 靸侅劯頌� 靹る獏頃╇媹雼�:

V-CO Investors LLC毳� 韱淀暣:

  • 514,498 氤错喌欤�
  • 靹犽秷 鞗岆煱韸� 2,705,768欤� (頄夓偓臧�瓴�: $0.0001, 毵岆: 2034雲�)
  • 氤错喌欤� 毵れ垬 鞗岆煱韸� 3,220,266欤� (頄夓偓臧�瓴�: $2.204, 毵岆: 2029雲�)

V-Co Investors 2 LLC毳� 韱淀暣:

  • 828,000 氤错喌欤�
  • 靹犽秷 鞗岆煱韸� 725,258欤� (頄夓偓臧�瓴�: $0.0001, 毵岆: 2035雲�)
  • 氤错喌欤� 毵れ垬 鞗岆煱韸� 2,329,886欤� (頄夓偓臧�瓴�: $2.23, 毵岆: 2030雲�)

鞀れ勾頂勲姅 霊� 韴瀽 靾橂嫧鞚� 甏�毽晿電� SP Manager LLC鞚� 鞝勲 鞚挫偓搿� 鞛 欷戩瀰雼堧嫟. 攴鸽姅 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃� 鞙犾澋 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.

Michael C. Skaff a d茅pos茅 une d茅claration initiale de propri茅t茅 b茅n茅ficiaire via le formulaire 3 pour Vivos Therapeutics (VVOS), indiquant une position de d茅tenteur de 10%. Le d茅p么t d茅taille des participations importantes via deux v茅hicules d'investissement :

Via V-CO Investors LLC :

  • 514 498 actions ordinaires
  • Warrant pr茅financ茅 pour 2 705 768 actions (prix d'exercice : 0,0001 $, expiration en 2034)
  • Warrant d'achat d'actions ordinaires pour 3 220 266 actions (prix d'exercice : 2,204 $, expiration en 2029)

Via V-Co Investors 2 LLC :

  • 828 000 actions ordinaires
  • Warrant pr茅financ茅 pour 725 258 actions (prix d'exercice : 0,0001 $, expiration en 2035)
  • Warrant d'achat d'actions ordinaires pour 2 329 886 actions (prix d'exercice : 2,23 $, expiration en 2030)

Skaff est directeur g茅n茅ral de SP Manager LLC, qui g猫re les deux v茅hicules d'investissement. Il d茅cline la propri茅t茅 b茅n茅ficiaire sauf pour son int茅r锚t p茅cuniaire.

Michael C. Skaff reichte eine erste Form 3-Erkl盲rung 眉ber den wirtschaftlichen Eigentum an Vivos Therapeutics (VVOS) ein und meldete eine Beteiligung von 10%. Die Einreichung beschreibt bedeutende Beteiligungen 眉ber zwei Investmentvehikel:

脺产别谤 V-CO Investors LLC:

  • 514.498 Stammaktien
  • Vorfinanzierte Optionsscheine f眉r 2.705.768 Aktien (Aus眉bungspreis: 0,0001 $, Ablauf 2034)
  • Optionsscheine zum Kauf von Stammaktien f眉r 3.220.266 Aktien (Aus眉bungspreis: 2,204 $, Ablauf 2029)

脺产别谤 V-Co Investors 2 LLC:

  • 828.000 Stammaktien
  • Vorfinanzierte Optionsscheine f眉r 725.258 Aktien (Aus眉bungspreis: 0,0001 $, Ablauf 2035)
  • Optionsscheine zum Kauf von Stammaktien f眉r 2.329.886 Aktien (Aus眉bungspreis: 2,23 $, Ablauf 2030)

Skaff ist Gesch盲ftsf眉hrer von SP Manager LLC, die beide Investmentvehikel verwaltet. Er lehnt das wirtschaftliche Eigentum ab, mit Ausnahme seines finanziellen Interesses.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Skaff Michael C
(Last) (First) (Middle)
TWO TOWNE SQUARE
STE. 810
(Street)
SOUTHFIELD MI 48076
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2025 		3. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 514,498 I By V-CO Investors LLC(1)
Common Stock 828,000 I By V-Co Investors 2 LLC(2)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-Funded Warrant 06/10/2024 06/10/2034(3) Common Stock 2,705,768 $0.0001 I By V-CO Investors LLC(1)
Common Stock Purchase Warrant 06/10/2024 06/10/2029 Common Stock 3,220,266 $2.204 I By V-CO Investors LLC(1)
Pre-Funded Warrant 06/09/2025 06/09/2035(3) Common Stock 725,258 $0.0001 I By V-Co Investors 2 LLC(2)
Common Stock Purchase Warrant 06/09/2025 06/09/2030 Common Stock 2,329,886 $2.23 I By V-Co Investors 2 LLC(2)
Explanation of Responses:
1. The Reporting Person serves as Managing Director of SP Manager LLC, the Manager of V-CO Investors LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
2. The Reporting Person serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 2 LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3. The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant.
Michael C. Skaff, as Managing Director SP Manager LLC, Manager of V-CO Investors LLC 06/20/2025
Michael C. Skaff, as Managing Director SP Manager LLC, Manager of V-Co Investors 2 LLC 06/20/2025
Michael C. Skaff, as Managing Director SP Manager LLC 06/20/2025
Michael C. Skaff, Individual 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of VVOS common stock does Michael Skaff beneficially own through V-CO Investors LLC?

Through V-CO Investors LLC, Michael Skaff beneficially owns 514,498 shares of VVOS common stock. However, as noted in the filing, he disclaims beneficial ownership except to the extent of his pecuniary interest as Managing Director of SP Manager LLC.

What warrants does Michael Skaff hold in VVOS through V-CO Investors LLC?

Through V-CO Investors LLC, Skaff holds two types of warrants: 1) A Pre-Funded Warrant for 2,705,768 shares exercisable at $0.0001 expiring June 10, 2034, and 2) A Common Stock Purchase Warrant for 3,220,266 shares exercisable at $2.204 expiring June 10, 2029.

What is Michael Skaff's relationship to VVOS according to the Form 3?

According to the Form 3, Michael Skaff is a 10% Owner of VVOS. He serves as Managing Director of SP Manager LLC, which is the Manager of both V-CO Investors LLC and V-Co Investors 2 LLC.

When did Michael Skaff acquire his most recent VVOS warrants?

The most recent warrants were acquired on June 9, 2025 through V-Co Investors 2 LLC, consisting of a Pre-Funded Warrant for 725,258 shares (exercisable at $0.0001, expiring June 9, 2035) and a Common Stock Purchase Warrant for 2,329,886 shares (exercisable at $2.23, expiring June 9, 2030).

What is the total direct and indirect common stock ownership of VVOS reported by Michael Skaff?

Michael Skaff reports indirect ownership of 1,342,498 shares of VVOS common stock in total, with 514,498 shares held through V-CO Investors LLC and 828,000 shares held through V-Co Investors 2 LLC. He reports no direct ownership of shares.
Stock VVOS logo
Vivos Therapeutics Inc

NASDAQ:VVOS

VVOS Rankings

#8682 Ranked by Market Cap
N/A Ranked by Dividends

VVOS Latest News

Jul 1, 2025
Vivos Therapeutics Receives Medicare Approval for VidaSleep鈩� Oral Appliance
Jun 26, 2025
New Clinical Trial Data Published Showing Positive Results from Use of聽Vivos Technology to Treat Obstructive Sleep Apnea in Children
Jun 11, 2025
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
May 15, 2025
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
May 14, 2025
Vivos Therapeutics Schedules Release of First Quarter 2025聽Financial Results and Conference Call

VVOS Stock Data

17.49M
4.25M
8%
13.7%
5.84%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
LITTLETON